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ABSTRACT 
 
Introduction 
Fatigue is very common in multiple sclerosis (MS) and is often considered as its most disabling 
symptom. Over the last twenty years, an increasing number of studies have evaluated the 
pathogenetic bases of MS-related fatigue. Converging evidence from neurophysiology and 
neuroimaging research suggests that a dysfunction in a cortico-subcortical pathway, centered on 
thalamus, is involved in the pathogenesis of fatigue. However, type and significance of such 
dysfunction remain unknown, and some studies reported an increase in the activity and connectivity 
within the thalamic network, whereas others suggested its reduction. 
Methods and Results 
Hereby, we review the results of neuroimaging studies supporting the different hypotheses about the 
role of thalamic network in the pathophysiology of MS-related fatigue, and discuss limitations and 
shortcomings of available data, highlighting the key challenges in the field and the directions for 
future research. 
 
 
INTRODUCTION 
Fatigue, defined as an overwhelming sense of lack of physical and/or mental energy, can affect up 
to 80% patients with multiple sclerosis (MS) and is often considered as its most disabling 
symptom.1,2 
 
Fatigue is a poorly defined construct and, hence, difficult to measure and to define in the clinical 
practice and trials.3 The MS International Federation identified two types of fatigue: i) physical 
fatigue, characterized by muscle weakness and difficulties to perform daily tasks, and ii) cognitive 
fatigue, characterized by difficulties in thinking, concentration, and memory.4 Fatigue is generally 
self-reported by patients, using questionnaires such as the Fatigue Severity Scale (FSS),5 and the 
Modified Fatigue Impact Scale (MFIS).6 Most frequently-used pharmacological treatments for 
fatigue are amantadine, 4-aminopyridine, and modafinil. Non-pharmacological interventions 
include physical (e.g., aerobic exercises, resistance training, yoga, tai-chi), and 
psychological/cognitive approaches (e.g., cognitive behavioural therapy, education programs, and 
mindfulness interventions).3 However, evidence supporting the efficacy of these interventions is 
still preliminary and, sometimes, conflicting. This depends, at least in part, by our poor 
understanding of the processes underlying fatigue in MS, and by the lack of validated and 
reproducible biomarkers (e.g., MRI). 
 
Over the last twenty years, an increasing number of studies have evaluated the pathogenetic bases 
of MS-related fatigue. Converging evidence from neurophysiology7,8 and neuroimaging9,10 
demonstrated that, in patients with MS, fatigue has a central origin and a dysfunction of the circuits 
between thalamus, basal ganglia and cortex could be its main pathogenic substrate. Initially, many 
authors focused on areas of possible interest for motor fatigue (cortex and basal ganglia), that were 
easy to investigate with neuroimaging and neurophysiological tools.7,8,11 However, the a priori 
choice of the region of interest (or seed region) has ignored the possible relevance of thalamus. 
More recently, thanks to the increasing interest in non-motor aspects of fatigue (i.e. cognitive, 
psychosocial) and the improved knowledge on the unique role of thalamus as a gateway for cortical 
areas and a relay between cortical and subcortical structures,12 thalamus has progressively gained 
attention in the study of pathophysiology of MS-related fatigue. Overall, a dysfunction in a cortico-
subcortical pathway, centered on thalamus, is involved in the pathogenesis of fatigue, but type and 
significance of such dysfunction remain unknown. Some studies reported an increase in the activity 
and connectivity of thalamic network,13–17 whereas others suggested its reduction.18–23 Thus, the 
role of thalamus in the pathogenesis of fatigue remains largely controversial and different 
hypotheses have been proposed. 
 
In the past, original studies and reviews on fatigue in MS have evaluated different brain regions, 
whilst, in this review, we have decided to focus on the most promising area in the pathophysiology 
of MS-related fatigue, the thalamus. In the first part, we will briefly report on normal structure of 
the thalamus and on its impairment in MS. Then, we will describe the results of neuroimaging 
studies supporting different hypotheses about the role of thalamic network in the pathophysiology 
of MS-related fatigue (increased vs decreased activity). We will then unify existing data to discuss 
potential neuroanatomical mechanisms to explain how damage in (or outside of) the thalamus leads 
to symptoms of fatigue. Finally, we will discuss limitations and shortcomings of available data, 
highlighting the key challenges in the field and directions for future clinical trials and observational 
studies. 
 
THALAMUS: NORMAL STRUCTURE AND FUNCTION 
The thalamus is the largest part of the diencephalon and is located between the third ventricle 
medially, and the internal capsule, laterally. The thalamus is extremely heterogeneous in its 
anatomical structure, functional connectivity and neuroimaging appearance, and different 
classifications have been proposed (Figure 1). 
 
Anatomically, the thalamus is divided into three regions (anterior, lateral and medial) by the 
internal medullary lamina. Within each of these regions, there are nuclei with distinct connections 
(Figure 1A). Other nuclei are located within the internal medullary lamina (intralaminar nuclei), 
and on the lateral aspect of the thalamus (reticular nucleus), out of the external medullary lamina. 
Finally, in the posterior area of the thalamus, there are the medial geniculate nucleus and the lateral 
geniculate nucleus. 
 
Functionally, thalamic nuclei can be divided into three basic types: the relay nuclei, the association 
nuclei and the non-specific nuclei24 (Figure 1B). Relay nuclei transmit information from the 
periphery to the cortex. Depending on the type of relayed information, they can be classified as: a) 
sensory relay nuclei acting as a gateway for sensory (somatosensory, visual, auditory) inputs to 
reach different sensory cortical areas;25 b) motor relay nuclei connecting subcortical motor 
structures, such as cerebellum and basal ganglia, with cortical motor areas such as primary motor 
and premotor cortex;26 limbic relay nuclei connecting different structures of the limbic system such 
as mammillary bodies, cingulate cortex, and entorhinal cortex.27 The association nuclei (e.g., 
pulvinar) receive input from the cerebral cortex and project back to the cerebral cortex and are 
supposed to regulate the activity of cortical association areas.28 The nonspecific nuclei (e.g., 
intralaminar and midline thalamic nuclei) send diffuse projections to the cerebral cortex and are 
probably involved in general functions such as alertness and arousal.29 
 
Recent advances in neuroimaging techniques have enabled to identify, non-invasively, connections 
between the main thalamic nuclei and the cortex, which have strong correspondence with the 
anatomical and functional classification of thalamic nuclei derived from animal and human ex vivo 
studies. Using a probabilistic tractography algorithm, Beherens et al.30 classified thalamic grey 
matter based on its connections with cortex and identified 6 main thalamic regions: frontal, 
occipital, parietal, temporal, precentral, postcentral regions. This thalamic classification has shown 
high reproducibility within and between subjects31 and has been confirmed on both functional MRI 
(fMRI)32,33 and DTI.34 
 
THALAMUS IN MS 
Evidence of thalamic involvement in MS arises mainly from neuropathological and neuroimaging 
studies. Neuropathological studies35,36 have shown demyelination, inflammation and 
neurodegeneration (i.e. neuronal loss, neuronal shrinkage and axonal damage) in the thalamus. 
These findings have been confirmed in vivo using different neuroimaging techniques. Volumetric 
MRI studies showed thalamic atrophy,37–39 since the very early stages of the disease, including 
clinically isolated syndrome (CIS), pediatric-onset MS and radiologically isolated syndrome.40 The 
development of advanced neuroimaging techniques, such as diffusion tensor imaging (DTI), has 
allowed to detect microstructural alterations in its nuclei and in the white matter tracts towards 
cortical and subcortical areas, also in absence of obvious thalamic atrophy.41–44 Taken together, 
neuroimaging and neuropathological studies suggest that thalamic damage in MS is common, 
occurs early and can be related to either a primary damage in thalamus or a distant damage of 
afferent or efferent thalamic fibers, subsequently affecting the thalamus through mechanisms of 
Wallerian or trans-neuronal degeneration.24  
 
THALAMUS AND FATIGUE IN MS 
The idea that thalamus could be involved in the pathophysiology of fatigue originally arises from 
studies showing structural and functional changes within the thalamus of fatigued MS patients. 
Different studies reported on thalamic atrophy along with basal ganglia and fronto-parietal cortex 
volume loss, in MS patients with fatigue.45,46 Moreover, advanced neuroimaging techniques showed 
indirect signs of demyelination and axonal loss in the thalamus of fatigued MS-patients.22,47,48 If a 
dysfunction in a cortico-subcortical pathway centered on thalamus is nowadays generally accepted 
as a determinant of fatigue in MS, contrasting results have been reported on type and significance of 
such dysfunction, with some studies reporting a reduction in the activity and connectivity of 
thalamic network,18–23 and others an increase.13–17 Differences between these findings have 
produced two main hypotheses about the potential neuroanatomical mechanisms to explain how 
thalamic impairment leads to fatigue, as discussed below (Figure 2).  
 
Reduced thalamic activity produces fatigue 
Fatigue can arise from a global reduction in the activity of networks involving thalamus, basal 
ganglia and cortex. Such reduction can be associated with measurable morphological changes 
(atrophy) in one or more parts of the network. Of note, functional connectivity may be increased 
between some areas of the network, as a compensatory strategy, whilst the global activity is 
globally reduced. This hypothesis is supported by studies showing a sustained reduction in thalamic 
functionality and connectivity in fatigued MS patients (Table 1). 
 
Roelcke et al.21 preliminarily described reduced glucose metabolism on 18F-fluorodeoxyglucose 
PET in the frontal cortex and in the basal ganglia of fatigued patients, when compared with not-
fatigued. A specific reduction of thalamic activity in fatigued MS patients was later described in 
another 18F-fluorodeoxyglucose PET study22, and also on MRI.18,20 In particular, Inglese et al.20 
found a significant association between fatigue severity and reduction of cerebral blood flow and 
volume in thalamus and basal ganglia by using dynamic susceptibility contrast enhanced T2*-
weighted MRI, as from thalamic dysfunction and damage. Filippi et al.18 demonstrated that 
activation of thalamus and sensorimotor cortical areas evoked by a simple motor task on fMRI was 
reduced in fatigued patients, when compared with not-fatigued. These findings were recently 
confirmed by Rocca et al.19 who showed, in a larger cohort, that fatigued patients have reduced 
activation in thalamus, basal ganglia and fronto-temporal-parietal cortex during a simple motor task, 
followed by abnormal adaption over time. Similarly, Bonzano et al.49 showed that fatigued MS 
patients presented with worse accuracy on repeated finger motor task and lower BOLD (Blood 
Oxygenation Level Dependent) signal, when compared with healthy subjects, that did not return to 
baseline level after rest. 
 Compensatory mechanisms to reduced thalamic activity and fatigue have been hypothesized. Cruz 
Gomez et al.23 found that fatigued MS patients presented with decreased levels of RS-MRI 
functional connectivity between areas related to sensory-motor functions (e.g., thalamus, 
cerebellum, brainstem, and frontal-parietal cortex), whilst not-fatigued patients displayed increased 
levels, as from compensatory mechanism reducing fatigue perception. Engstrom et al.16 found that 
fatigued MS patients have weaker cortical-to-subcortical connections, but stronger cortical-to-
cortical (left posterior parietal cortex and left dorsolateral prefrontal cortex) and subcortical-to-
subcortical (right substantia nigra and left thalamus) connections, possibly also acting as a 
compensatory mechanism. 
 
Fatigue is caused by a compensatory thalamic activity increase 
In this hypothesis, fatigue arises from an increase in the activity of the networks involving 
thalamus, basal ganglia and cortex, as a result of a compensatory mechanism that allows to maintain 
normal functioning but also produces fatigue. This hypothesis is supported by the results of a 
number of studies showing an increased activation in thalamus, basal ganglia and fronto-parietal-
occipital cortex in fatigued MS patients who performed a cognitive task during fMRI, when 
compared with controls or with not-fatigued patients (Table 2). 
 
Rocca et al.13 found that patients experiencing fatigue after Interferon-beta injections have an 
increased activation of thalamus and frontal cortex compared with patients without fatigue. Zhou et 
al.17 found that fatigued patients exhibited changes in the thalamocortical system consisting in 
structural disconnections at DTI and hyperconnectivity at RS-fMRI, further supporting that fatigue 
could arise from increased functional connectivity as a compensation to the microstructural damage 
in the thalamocortical network. 
 
TOWARDS A UNIFYING THEORY  
Discrepancies between the above-mentioned studies could be referred to different patterns of 
(increased or reduced) activation/connectivity, in different parts of the thalamocortical network, at 
different stages of disease. In early stages, patients could compensate MS-related structural damage 
by plasticity mechanisms leading to overactivation of the cortical-subcortical network without 
experiencing any fatigue. Over time, functional reserve reduces, with an additional effort to 
maintain the overactivation of the network, leading to transient fatigue. Once plasticity is not able to 
compensate the reduced structural connectivity, functional connectivity drops, and fatigue becomes 
chronically present. Not least, the structural and functional complexity of the thalamus has not been 
fully accounted, with most studies considering the thalamus as single region of interest. Preliminary 
data from volumetric45 and functional MRI studies10 showed that different circuits or different parts 
of the same circuit within the basal ganglia-thalamus-cortex network could be involved in the 
pathogenesis of different aspects of fatigue. 
 
To the best of our knowledge, no longitudinal studies have examined patients over time to assess 
whether fatigue-related brain patterns change over time. Thus, this hypothesis is solely based on the 
integration of the results from different studies that have investigated patients at different stages of 
MS. Accordingly, in patients with mild disability and short disease duration, fatigue is associated 
with microstructural damage in the thalamocortical pathway, compensated by hyperconnectivity at 
fMRI.17 On the contrary, in patients with more advanced disease, the structural damage of the 
thalamocortical system is associated with decreased levels of functional connectivity.23 
 
In light of the extent of thalamic connections between different cortical and subcortical areas, 
thalamic pathology in MS could be secondary to a damage of afferent or efferent thalamic fibers.24 
According to this hypothesis, fatigue may be related to a non-specific, MS-induced disconnection 
between different brain regions, with thalamic abnormalities (atrophy, microstructural changes) 
being an epiphenomenon of MS pathology occurring elsewhere than thalamus. This hypothesis is 
supported by studies showing that fatigue is associated to a widespread microstructural change in 
the white matter,50,51 or to a pathology of other structures different from thalamus, such as frontal52 
and primary somatosensory53 cortex. However, widespread white matter involvement could be 
representative of more advanced MS, masking the relevance of specific structures (i.e., thalamus) in 
the pathogenesis of fatigue. 
 
The specific role for thalamus in the pathogenesis of fatigue has been confirmed in both healthy 
subjects,54 and patients with different (and more focal) neurological diseases (e.g., stroke, traumatic 
brain injury).55,56 Indeed, a relatively-small damage to the thalamic network, independently from the 
extent of diffuse brain involvement, could generate fatigue. Accordingly, in MS, microstructural 
abnormalities and atrophy in strategic brain regions (e.g., thalamus) have stronger associations with 
fatigue, than measures of global brain damage, such as atrophy and lesion load.9,47 Not least, 
thalamus can be affected selectively, since the earliest stages of the disease, and independently from 
the extent of white matter involvement.12 
 
CONCLUSIONS, LIMITATIONS AND FUTURE RESEARCH 
Neuroimaging studies have demonstrated that the thalamus is involved in the pathogenesis of MS-
related fatigue, either as a cause or as a consequence of impaired cortical-subcortical networks. 
Though a number of brain regions contribute to the pathogenesis of fatigue,50,52,53,57,58 thalamus is a 
strategic area and a relatively-small disruption of its network can generate fatigue, independently 
from the extent of tissue involvement.9,59 In this review, we specifically focused on the results of 
neuroimaging studies supporting the role of the thalamic network in the pathophysiology of MS-
related fatigue. 
 
Future studies will have to clarify the role of thalamus within the pathogenesis of MS-related 
fatigue, overcoming the limitations of available data by: i) combining different neuroimaging and 
neurophysiological techniques (e.g. EEG-TMS, non-invasive brain stimulation) in the same sample 
to obtain multiparametric data; ii) investigating patients at different stages of disease (CIS, 
advanced progressive MS); iii) assessing whether thalamic impairment is primary or secondary to 
the damage of other structures outside of the thalamus (e.g., diffuse white matter damage) with a 
longitudinal design; iv) considering separately different thalamic nuclei and their connections; v) 
evaluating possible factors that contribute to fatigue pathogenesis and/or exacerbate its 
manifestations and perception (demographics, comorbidity, genetics, diet, exercise, depression, 
cognitive impairment, pain and sleep disorders).60–63 
 
The management of fatigue requires a multidisciplinary approach including both pharmacological 
and non-pharmacological interventions, but the evidence supporting their efficacy is still 
preliminary. Result heterogeneity could be due to methodological differences among studies in 
terms of sample (e.g., disease duration), and definition of fatigue, with very few studies including 
neuroimaging protocols. Clinical trials on MS-related fatigue treatments have sometimes requested 
MRI for baseline patients’ stratification.64,65 Despite variations in thalamic activity were associated 
with fatigue development in an open-label study on Interferon-Beta1a-treated patients,13 so far, only 
one clinical trial (evaluating acupuncture and mindfulness for MS fatigue) included functional 
connectivity on fMRI as a tertiary outcome measure in a subgroup of patients.66 Thus, a validated 
and reproducible set of measures for the thalamic network could be used to i) identifying subgroups 
of fatigued patients, that share common pathogenetic mechanisms, ii) quantifying objectively the 
subjective experience of fatigue, and iii) evaluating the efficacy of therapeutic interventions, 
ultimately leading to tailored pharmacological and non-pharmacological management of fatigue. 
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Table 1. Imaging studies showing reduced thalamic volume, microstructure and activity in MS patients with fatigue. 
Table shows studies showing reduced thalamic volume (on structural imaging), microstructure (on DTI) and activity in relation to MS fatigue (on 
functional, metabolic and perfusion imaging). Imaging technique, population characteristics, fatigue assessment, main findings and limitations are 
reported. 
 
Imaging Technique Population Fatigue scale 
(assessor) 
Main findings in fatigued patients 
(compared with HC and/or not-fatigued 
patients) 
Limitations Reference 
Structural imaging      
1.5T MRI RRMS (n=60) 
HC (n=18) 
FSS 
(self-reported) 
↑↑↑ atrophy in areas related to the 
sensory-motor network. 
Significant difference in 
EDSS between fatigued 
and not fatigued 
patients. 
Cruz-Gomez et 
al, Plos One, 
2013 
Microstructural imaging 
3T MRI (DTI) RRMS (n=79) 
HC (n=40) 
FSMC 
(self-reported) 
↓↓↓ FA in thalamus and basal ganglia 
↑↑↑ MD in thalamus and basal ganglia  
(in absence of differences in thalamic 
volume) 
HC not well matched. Wilting J et al, 
Eur Radiol 
2016 
Functional imaging      
1.5T fMRI  
(motor task with 
dominant hand) 
RRMS (n=29) 
HC (n=15) 
FSS 
(self-reported) 
↓↓↓ activation in contralateral thalamus 
and intraparietal sulcus, and in ipsilateral 
thalamus and rolandic operculum. 
Small sample size Filippi M et al, 
Neuroimage 
2002 
3T fMRI 
(motor task with 
dominant hand) 
RRMS (n=79) 
HC (n=26) 
MFIS 
(self-reported) 
↓↓↓ activation in the fronto-temporal-
parietal regions, basal ganglia, thalamus 
and supplementary motor area. 
↑↑↑ activation in the ipsilateral middle 
frontal gyrus. 
Analysis restricted to 
the motor network 
Rocca MA et 
al, Mult Scler. 
2016 
3T rs-fMRI RRMS (n=22) 
HC (n=12) 
FSMC 
(self-reported) 
Immediate ↑↑↑ FC between frontal cortex 
and caudate 
Delayed ↓↓↓ FC within thalamus 
Small sample size 
Patients not well 
matched. 
Pravata’ et al, 
Mult Scler 
2016 
1.5T fMRI 
(demanding motor task 
with dominant hand) 
RRMS (n=14) MFIS 
(self-reported) 
↓↓↓ activation in contralateral thalamus, 
basal ganglia and amigdala. 
Absence of a control 
group. 
Small sample size 
Bonzano L et 
al, Behav 
Brain Res. 
2017 
1.5T rs-fMRI RRMS (n=60) FSS ↓↓↓ FC between the supplementary motor Significant difference in Cruz-Gomez et 
HC (n=18) (self-reported) area and associative somatosensory cortex. EDSS between fatigued 
and not fatigued 
patients. 
al, Plos One, 
2013 
1.5T fMRI 
(working memory task) 
 
 
1.5T rs-fMRI 
RRMS (n=11) 
SPMS (n=3) 
PPMS (n=1) 
HC (n=11) 
Self-reported 
fatigue and heat 
sensitivity 
(self-reported) 
↓↓↓ activation in thalamus, basal ganglia 
and frontal cortex. 
↑↑↑ activation in the parietal cortex. 
 
↑↑↑ FC within the cerebral cortex and 
within subcortical regions, 
↓↓↓ FC between cerebral cortex and 
striatum. 
Lack of standardized 
fatigue assessment 
Possible cognitive 
impairment 
Engstrom et al, 
Brain Behav. 
2013 
Metabolic imaging      
[18F]-FDG-PET 
 
RRMS (n=17) MFIS 
(self-reported) 
↓↓↓ [18F]-FDG uptake in the GM of 
frontal and temporal regions, and in 
bilateral thalamus and basal ganglia. 
Measurements limited 
to the GM. 
Absence of a control 
group. 
Small sample size. 
Derache N et 
al, Mult Scler 
Relat Disord. 
2013 
Perfusion imaging      
3T MRI (perfusion 
measures) 
RRMS (n=11) 
PPMS (n=11) 
HC (n=11) 
Multidimensional 
Fatigue 
Inventory 
(psychologist) 
↓↓↓ cerebral blood flow and cerebral 
blood volume in deep GM. 
Measurements limited 
to deep GM. 
Small sample size. 
Concomitant 
immunomodulatory 
treatments. 
Inglese M et 
al, Arch 
Neurol. 2007 
MS: multiple sclerosis; MRI: magnetic resonance imaging; DTI: diffusion tensor imaging; fMRI: functional MRI; RRMS: relapsing-remitting MS; 
HC: healthy control; FSS: Fatigue Severity Scale; MFIS: Modified Fatigue Impact Scale; RS: resting state; GM: grey matter; PPMS: primary 
progressive MS; SPMS: secondary progressive MS; FC: functional connectivity. 
 
Table 2. Imaging studies showing increased thalamic activity in MS patients with fatigue. 
Table shows studies showing increased thalamic activity in relation to MS fatigue (on functional imaging). Imaging technique, population 
characteristics, fatigue assessment, main findings and limitations are reported. 
 
Imaging Technique Population Fatigue scale 
(assessor) 
Main findings in fatigued patients 
(compared with HC and/or not-fatigued 
patients) 
Limitations Reference 
Functional imaging     
3T fMRI 
(cognitive task) 
RRMS (n=12) 
PPMS (n=3) 
HC (n=15) 
mSDMT score 
(psychologist) 
↑↑↑ activation in thalamus, basal ganglia and 
fronto-parietal-occipital cortex. 
Neuropsychological 
fatigue, without self-
reported fatigue. 
Small sample size. 
DeLuca J et al, J 
Neurol Sci. 2008 
3T fMRI 
(task-switching task) 
RRMS (n=9) 
PPMS (n=1) 
SPMS (n=1) 
HC (n=11) 
Self-reported 
cognitive 
fatigue 
(self-reported) 
↑↑↑ activation in prefrontal cortex, left 
postcentral gyrus, precuneus, precentral gyrus, 
inferior temporal gyrus, and declive of the 
cerebellum. 
↓↓↓ activation in the left superior frontal gyrus, 
right cuneus and bilateral temporal regions. 
(in presence of microstructural impairment on 
DTI, with ↓↓↓ FA in the anterior internal 
capsule) 
Neuropsychological 
fatigue, without self-
reported fatigue. 
HC not well 
matched. 
Small sample size. 
Genova et al, 
PLoS One. 2013 
1.5 fMRI 
(motor task with 
dominant hand) 
RRMS (n=22) FSS 
(self-reported) 
↑↑↑ activations of thalamus and frontal cortex  Reversible 
Interferon-induced 
fatigue. 
Absence of a control 
group. 
Rocca et al, Hum 
Brain Mapp. 2007 
3T rs-fMRI RRMS (n=20) 
HC (n=20) 
MFIS 
(self-reported) 
↑↑↑ FC in thalamocortical pathways 
(in presence of microstructural impairment on 
DTI, with ↑↑↑ MD and RD in the 
thalamocortical somatosensory WM tract, and 
↑↑↑ AD in the thalamocortical prefrontal WM 
tract) 
Poor standardization 
of MRI methods   
Zhou et al, Front 
Hum Neurosci 
2016 
RRMS (n=20) 
HC (n=20)MFIS 
(self-reported)MS: multiple sclerosis; MRI: magnetic resonance imaging; fMRI: functional MRI; RRMS: relapsing-remitting MS; HC: healthy 
control; FSS: Fatigue Severity Scale; MFIS: Modified Fatigue Impact Scale; RS: resting state; GM: grey matter; WM: white matter; PPMS: primary 
progressive MS; SPMS: secondary progressive MS; FC: functional connectivity; FA: fractional anisotropy; MD: mean diffusivity; RD: radial 
diffusivity; AD: axial diffusivity; FSMC: Fatigue Scale for Motor and Cognitive Functions; DTI: diffusion tensor imaging. 
Figure 1. Anatomical and functional classification of the thalamus. 
Anatomically (A), the thalamus is divided by the internal medullary lamina (green) into anterior 
nucleus (red), lateral region (containing lateral dorsal, ventral anterior, ventral lateral, ventral 
posterior and lateral posterior nuclei, in blue), medial region (yellow), and posterior region 
(including pulvinar, medial geniculate and lateral geniculate nuclei, in violet). 
Functionally (B), thalamic nuclei can be divided into relay nuclei, association nuclei and non-
specific nuclei. Sensory relay nuclei send somatosensory (red), visual (pink), and auditory (green) 
inputs to different sensory cortical areas. Motor relay nuclei connect subcortical motor structures 
with cortical motor areas (blue). Limbic relay nuclei connect different structures of the limbic 
system (violet). The association nuclei receive input from the cerebral cortex and project back to the 
cerebral cortex (orange). The nonspecific nuclei send diffuse projections to the cerebral cortex. 
 
 
Figure 2. Normal thalamic function and possible changes in fatigued patients. 
In healthy subjects, thalamus acts as a relay between different cortical and subcortical areas (A). In 
fatigued MS patients, fatigue can arise from an increase in the activity of the network, as a result of 
a compensatory mechanism that allows to maintain normal functioning but also produces fatigue 
(B). Alternatively, fatigue can arise from a global reduction in the activity of the network involving 
thalamus, basal ganglia and cortex (C). 
 
 
 
